Izamby

Denosumab, the active ingredient in Izamby, is a monoclonal antibody presented as a 60 mg/1 mL prefilled syringe injection solution for subcutaneous use. It is indicated for osteoporosis in postmenopausal women and men at high risk of fracture, as well as for bone loss associated with glucocorticoid therapy.

GNH USA supplies Izamby as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under EU‑market standards. Our distribution network ensures consistent quality and regulatory compliance across regions.

Izamby (denosumab) is a bone resorption inhibitor used in conditions characterized by increased osteoclast activity.

- Postmenopausal osteoporosis: reduces risk of vertebral, non‑vertebral and hip fractures in women at high fracture risk. - Male osteoporosis: lowers fracture incidence in men with high fracture risk. - Glucocorticoid‑induced bone loss: prevents bone density loss in patients receiving long‑term glucocorticoid therapy.

Common and serious adverse reactions have been reported with denosumab therapy.

Common Side Effects: - Injection site reactions: pain, redness or swelling at the injection site. - Upper respiratory infections: mild to moderate nasopharyngitis. - Musculoskeletal pain: joint or muscle discomfort. - Dermatologic events: rash or eczema.

Serious or Rare Side Effects: - Hypocalcemia: low blood calcium levels, potentially symptomatic. - Osteonecrosis of the jaw (ONJ): exposed necrotic bone in the maxillofacial region. - Atypical femoral fractures: low‑energy fractures of the femoral shaft. - Severe hypersensitivity: anaphylaxis or angioedema.

Before initiating Izamby, clinicians should consider several precautionary measures to ensure safe use. - Calcium and vitamin D status: ensure adequate supplementation to reduce hypocalcemia risk. - Renal function: assess kidney function, as severe impairment may increase hypocalcemia. - Dental health: perform dental examination and complete invasive procedures before starting therapy. - History of ONJ: avoid use in patients with prior osteonecrosis of the jaw. - Concomitant medications: review use of other bone‑active agents, such as bisphosphonates, for potential additive effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Denosumab may interact with other medicines, affecting calcium balance or bone metabolism.

Major Interactions (Avoid): - Calcium‑lowering agents: concurrent high‑dose calcitonin may increase risk of severe hypocalcemia. - Immunosuppressants: potent agents (e.g., high‑dose steroids) may mask infection signs.

Moderate Interactions (Monitor Closely): - Vitamin D analogues: adjust dosing to maintain calcium levels. - Bisphosphonates: sequential therapy may increase risk of ONJ; monitor dental health. - Anticonvulsants (e.g., phenytoin): may reduce vitamin D levels, requiring monitoring. - Hormone replacement therapy: may have additive effects on bone density; observe response.